Literature DB >> 16214811

Regulation of the type I IFN induction: a current view.

Kenya Honda1, Hideyuki Yanai, Akinori Takaoka, Tadatsugu Taniguchi.   

Abstract

The type I IFN-alpha/beta gene family was identified about a quarter of a century ago as a prototype of many cytokine gene families, which led to the subsequent burst of studies on molecular mechanisms underlying cytokine gene expression and signaling. Although originally discovered for their activity to confer an antiviral state on cells, more evidence has recently been emerging regarding IFN-alpha/beta actions on cell growth, differentiation and many immunoregulatory activities, which are of even greater fundamental biological significance. Indeed, much attention has recently been focused on the induction and function of the IFN-alpha/beta system regulated by Toll-like receptors (TLRs), which are critical for linking the innate and adaptive immunities. The understanding of the regulatory mechanisms of IFN-alpha/beta gene induction by TLRs and viruses is an emerging theme, for which much new insight has been gained over the past few years.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214811     DOI: 10.1093/intimm/dxh318

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  145 in total

Review 1.  Control of antiviral immunity by pattern recognition and the microbiome.

Authors:  Iris K Pang; Akiko Iwasaki
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  PIASy inhibits virus-induced and interferon-stimulated transcription through distinct mechanisms.

Authors:  Toru Kubota; Mayumi Matsuoka; Songxiao Xu; Noriyuki Otsuki; Makoto Takeda; Atsushi Kato; Keiko Ozato
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

3.  Mechanisms of autoinhibition of IRF-7 and a probable model for inactivation of IRF-7 by Kaposi's sarcoma-associated herpesvirus protein ORF45.

Authors:  Narayanan Sathish; Fan Xiu Zhu; Ellis E Golub; Qiming Liang; Yan Yuan
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

4.  Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling.

Authors:  Mariana G Bego; Johanne Mercier; Eric A Cohen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells.

Authors:  Leila N Laredj; Peter Beard
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

6.  Associations between PXK and TYK2 polymorphisms and systemic lupus erythematosus: a meta-analysis.

Authors:  Young Ho Lee; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Inflamm Res       Date:  2012-05-17       Impact factor: 4.575

7.  Bryostatin-1, a naturally occurring antineoplastic agent, acts as a Toll-like receptor 4 (TLR-4) ligand and induces unique cytokines and chemokines in dendritic cells.

Authors:  Maria Eugenia Ariza; Rupal Ramakrishnan; Narendra P Singh; Ashok Chauhan; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Biol Chem       Date:  2010-10-29       Impact factor: 5.157

8.  PRDM16 represses the type I interferon response in adipocytes to promote mitochondrial and thermogenic programing.

Authors:  Megan Kissig; Jeff Ishibashi; Matthew J Harms; Hee-Woong Lim; Rachel R Stine; Kyoung-Jae Won; Patrick Seale
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

9.  E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.

Authors:  Enguang Bi; Rong Li; Laura C Bover; Haiyan Li; Pan Su; Xingzhe Ma; Chunjian Huang; Qiang Wang; Lintao Liu; Maojie Yang; Zhijuan Lin; Jianfei Qian; Weijun Fu; Yong-Jun Liu; Qing Yi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

Review 10.  MHC class II regulation by epigenetic agents and microRNAs.

Authors:  Thomas B Tomasi; William J Magner; Jennifer L Wiesen; Julian Z Oshlag; Felicia Cao; Alex N Pontikos; Christopher J Gregorie
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.